Zydus Lifesciences Gets US FDA Nod for Eltrombopag Tablets

• Zydus Lifesciences received final US FDA approval for Eltrombopag Tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
• Eltrombopag treats thrombocytopenia (low platelet count) linked to specific blood disorders by stimulating platelet production.
• The tablets will be manufactured at Zydus's SEZ formulation facility in Ahmedabad.
• Eltrombopag recorded annual US sales of $1,262.5 million as per IQVIA MAT data for November 2025.
• This approval brings Zydus's cumulative USFDA approvals to 429, with 505 ANDAs filed since FY2003-04.

Why It Matters: Zydus Lifesciences secures crucial US FDA approval for Eltrombopag Tablets, boosting its pharmaceutical portfolio.